NCT01167816View on ClinicalTrials.gov

Phase I Trial of 5-Azacitidine Plus Gemcitabine in Patients With Advanced Pancreatic Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Pancreatic Cancer

Interventions

DRUG

Vidaza

Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle

Trial Locations (1)

73104

Stephenson Cancer Center, Oklahoma City

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

University of Oklahoma

OTHER